Atea Pharmaceuticals, Inc. (AVIR) Friday said its Phase 3 SUNRISE-3 study of bemnifosbuvir for the treatment of Covid-19 failed to meet the primary goal.
In the study, high-risk patients with mild or moderate COVID-19 were randomized to receive bemnifosbuvir or placebo. The trial did not meet the primary endpoint of a statistically significant reduction in all-cause hospitalization or death through day 29.
Bemnifosbuvir is in Phase 2 study in combination with ruzasvir for the treatment of hepatitis c virus (HCV) infection. The company plans to announce additional results from the study in the fourth quarter.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.